{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:18:35Z","timestamp":1783095515019,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["202309PJT-506896-C2-CEBA-108276"],"award-info":[{"award-number":["202309PJT-506896-C2-CEBA-108276"]}],"id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005046","name":"Heilongjiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["PL2024H020"],"award-info":[{"award-number":["PL2024H020"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.tranon.2026.102820","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:26:09Z","timestamp":1779096369000},"page":"102820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Sig27 multigene stratifies breast cancer fatality risk via reflecting tumor-associated immune suppressive features"],"prefix":"10.1016","volume":"69","author":[{"given":"Yingying","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-9521","authenticated-orcid":false,"given":"Damu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2026.102820_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.tranon.2026.102820_bib0002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"6797","key":"10.1016\/j.tranon.2026.102820_bib0003","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102820_bib0004","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"10869","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001"},{"key":"10.1016\/j.tranon.2026.102820_bib0005","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","article-title":"Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on tumor markers (EGTM)","volume":"75","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2026.102820_bib0006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5152\/ejbh.2017.3635","article-title":"Reliable biomarkers to identify new and recurrent cancer","volume":"13","author":"Sauter","year":"2017","journal-title":"Eur. J. Breast. Health"},{"issue":"7","key":"10.1016\/j.tranon.2026.102820_bib0007","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/genes14071364","article-title":"Biomarkers in breast cancer: an old story with a new end","volume":"14","author":"Neves Rebello Alves","year":"2023","journal-title":"Genes (Basel)"},{"issue":"21","key":"10.1016\/j.tranon.2026.102820_bib0008","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.tranon.2026.102820_bib0009","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","article-title":"West German Study Group Phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by Central and local pathology assessment","volume":"34","author":"Gluz","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102820_bib0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.tranon.2026.102820_bib0011","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102820_bib0012","doi-asserted-by":"crossref","first-page":"BMI.S6184","DOI":"10.4137\/BMI.S6184","article-title":"Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer","volume":"5","author":"Tian","year":"2010","journal-title":"Biomark. Insight."},{"issue":"3","key":"10.1016\/j.tranon.2026.102820_bib0013","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2026.102820_bib0014","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/cancers13030430","article-title":"Effective prediction of prostate cancer recurrence through the IQGAP1 network","volume":"13","author":"Gu","year":"2021","journal-title":"Cancer. (Basel)"},{"issue":"1","key":"10.1016\/j.tranon.2026.102820_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-022-02584-y","article-title":"PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity","volume":"42","author":"Gu","year":"2023","journal-title":"J. Exper. Clin. Cancer Res.: CR"},{"key":"10.1016\/j.tranon.2026.102820_bib0016","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jare.2023.01.015","article-title":"IQGAP3 is relevant to prostate cancer: a detailed presentation of potential pathomechanisms","volume":"54","author":"Mei","year":"2023","journal-title":"J. Adv. Res."},{"issue":"D1","key":"10.1016\/j.tranon.2026.102820_bib0017","doi-asserted-by":"crossref","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","article-title":"TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment","volume":"51","author":"Han","year":"2023","journal-title":"Nucl. Acid. Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102820_bib0018","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"issue":"D1","key":"10.1016\/j.tranon.2026.102820_bib0019","doi-asserted-by":"crossref","first-page":"D886","DOI":"10.1093\/nar\/gkae1142","article-title":"CZ CELLxGENE Discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data","volume":"53","author":"Program","year":"2025","journal-title":"Nucl. Acid. Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.102820_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygeno.2014.03.001","article-title":"YuGene: a simple approach to scale gene expression data derived from different platforms for integrated analyses","volume":"103","author":"Le Cao","year":"2014","journal-title":"Genomics"},{"issue":"11","key":"10.1016\/j.tranon.2026.102820_bib0021","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","article-title":"A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features","volume":"30","author":"Klughammer","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.tranon.2026.102820_bib0022","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr. Breast. Cancer Rep."},{"issue":"6","key":"10.1016\/j.tranon.2026.102820_bib0023","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.tranon.2026.102820_bib0024","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.tranon.2026.102820_bib0025","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.tranon.2026.102820_bib0026","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.tranon.2026.102820_bib0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s12276-023-00941-1","article-title":"Formyl peptide receptor 2 is an emerging modulator of inflammation in the liver","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.102820_bib0028","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00432-019-02901-7","article-title":"NOD1 and NOD2 of the innate immune system is differently expressed in human clear cell renal cell carcinoma, corresponding healthy renal tissue, its vasculature and primary isolated renal tubular epithelial cells","volume":"145","author":"Mey","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102820_bib0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminoncol.2017.10.013","article-title":"LAMPs: shedding light on cancer biology","volume":"44","author":"Alessandrini","year":"2017","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102820_bib0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","article-title":"The role of tumor-associated macrophages in tumor immune evasion","volume":"150","author":"Huang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.102820_bib0031","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3390\/biomedicines12102381","article-title":"Insights into CSF-1R expression in the tumor microenvironment","volume":"12","author":"Tomassetti","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.tranon.2026.102820_bib0032","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4049\/jimmunol.178.3.1450","article-title":"F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor","volume":"178","author":"Gao","year":"2007","journal-title":"J. Immunol."},{"issue":"21","key":"10.1016\/j.tranon.2026.102820_bib0033","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102820_bib0034","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"17858","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009"},{"issue":"2","key":"10.1016\/j.tranon.2026.102820_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1084\/jem.20150785","article-title":"Identification of CD112R as a novel checkpoint for human T cells","volume":"213","author":"Zhu","year":"2016","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.tranon.2026.102820_bib0036","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","article-title":"Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)","volume":"172","author":"Fuchs","year":"2004","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102820_bib0037","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0326","article-title":"Sig27 stratifies prostate cancer recurrence by assessing the immunosuppressive properties of tumors","volume":"32","author":"Neira","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102820_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.tranon.2026.102820_bib0039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s44276-025-00128-3","article-title":"A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features","volume":"3","author":"Dong","year":"2025","journal-title":"BJC Rep."},{"issue":"2","key":"10.1016\/j.tranon.2026.102820_bib0040","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7150\/ijbs.65457","article-title":"Role of RHO family interacting cell polarization regulators (RIPORs) in health and disease: recent advances and prospects","volume":"18","author":"Lv","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.tranon.2026.102820_bib0041","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1148\/rg.345130049","article-title":"Molecular classification of infiltrating breast cancer: toward personalized therapy","volume":"34","author":"Trop","year":"2014","journal-title":"Radiographics"},{"issue":"19","key":"10.1016\/j.tranon.2026.102820_bib0042","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.3390\/cancers16193250","article-title":"Present and future of immunotherapy for triple-negative breast cancer","volume":"16","author":"Sriramulu","year":"2024","journal-title":"Cancer. (Basel)"},{"issue":"4","key":"10.1016\/j.tranon.2026.102820_bib0043","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clbc.2024.03.001","article-title":"The role of immunotherapy in triple-negative breast cancer (TNBC)","volume":"24","author":"Michaels","year":"2024","journal-title":"Clin. Breast. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.102820_bib0044","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40487-025-00346-2","article-title":"Immunotherapy in triple-negative breast cancer","volume":"13","author":"Tiberi","year":"2025","journal-title":"Oncol. Ther."},{"issue":"2","key":"10.1016\/j.tranon.2026.102820_bib0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"10.1016\/j.tranon.2026.102820_bib0046","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-016-0161-x","article-title":"Biomarkers immune monitoring technology primer: immunoscore(R) Colon","volume":"4","author":"Hermitte","year":"2016","journal-title":"J. Immunother. Cancer."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:25:34Z","timestamp":1783092334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"alternative-id":["S1936523326001579"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102820","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Sig27 multigene stratifies breast cancer fatality risk via reflecting tumor-associated immune suppressive features","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102820"}}